CellCyte Genetics Corp. (CCYG.OB) has announced the appointment of Tony Calasin as the company’s Director of Business Development. Tony Calasin will primarily focus on CellCyte’s acquisition and technology licensing, amongst various other tasks.
Tony Colasin, from January 2001 to January 2007, was employed as the Sr. Director of Business Development for ICOS Corporation. During this time period, Tony directed ICOS’ business development during several major product introductions. More notably, Tony Colasin was also responsible for building a urology franchise to leverage the Cialis brand. Cialis is a treatment for erectile dysfunction that, thanks to Colasin’s direction, successfully launched against the primary drug candidate Viagra.
Prior to being employed at ICOS Corporation and Cialis, Mr. Colasin also served as a Sr. Finance Manager for Amgen, Inc. During his period at Amgen, Colasin was responsible for the evaluation of drug candidates and management of such drugs. Furthermore, Colasin was also a Financial Analyst for the $1 billion drug EPOGEN from February 1996 to June 1997. In his early roles with the company, he played a vital part in analyzing forecasts, financial models and sales trends critical to products and markets that the company was pursuing.
Tony Colasin graduated from University of Southern California with a B.S., Business Administration. Shortly thereafter, Colasin received his M.B.A in Finance with an International Business Emphasis from the Anderson School at UCLA.
Let us hear your thoughts below:
